Developer docs
API playgroundTry for free, no card

Search company profiles

REPROSENT

Full company profile

uuid00021rl

Namestring
REPROSENT
Legal namestring
REPROSENT
Websiteurl
reprosent.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

REPROSENT is a healthcare technology company founded in 2020 and headquartered in San Francisco that operates a platform branded as the "Signal Layer," a human-signal layer for oncology clinical trials. The platform captures patient-reported symptoms and outcomes in oncology studies through an EHR-agnostic, non-interventional observational overlay, positioning REPROSENT as a data-infrastructure layer that sits between protocol-driven electronic data capture and the real-world symptom experience of cancer patients on therapy. Its core technical claim is the production of structured, AI-ready longitudinal datasets from patient-reported inputs collected outside clinic visits, including dose-aware signals that can be reused across trial programs.

The company's commercial model is subscription or recurring platform licensing, sold into biopharmaceutical development and medical teams as the primary customer segment, with a secondary segment of cooperative groups and cancer centers. Beyond core trial data capture, REPROSENT positions the platform for reuse in health economics and outcomes research (HEOR), digital biomarker development, and AI model training, implying a land-and-expand strategy where a single trial deployment seeds downstream analytic and licensing revenue. No public pricing, contract terms, customer count, or ARR figures are disclosed.

REPROSENT is a small, leanly capitalized company operating with 1-10 employees. Cumulative outside capital disclosed to date is approximately $225,000, consisting of a $125,000 investment from Y Combinator in August 2021 and a $100,000 grant from the Astellas C3 Prize in August 2022. The Astellas award is also the source of the company's only publicly named industry relationship to date. Operations are described as global despite a US-only headquarters footprint, though international commercial activity is not separately verified in the available material.

Short descriptiontext

REPROSENT operates the Signal Layer, an EHR-agnostic patient-reported outcomes platform for oncology clinical trials. It sells subscription licensing to biopharma development teams and cancer centers, capturing longitudinal, AI-ready symptom data outside clinic visits for reuse in HEOR, biomarkers, and AI training.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
patient-reported outcomes, oncology clinical trials, tolerability data capture, EHR-integrated platform, digital health SaaS
Industry4 codes
PRIMARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
SECONDARYHLACAEAO
Patient Relationship Management (PRM) & CRM for Provider Growth (Marketing/Outreach)
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Oncology Patient-Reported Outcomes Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform/SaaS Licensing
TypeSubscription Recurring
Description

REPROSENT provides its human-signal layer as an observational overlay to biopharma companies, cooperative groups, and cancer centers. The platform is deployed alongside existing trials and care programs, suggesting a subscription or licensing model for enterprise clients.

reprosent.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

REPROSENT sells a "Human-Signal Layer for Oncology" called Signal Layer, a SaaS platform that captures patient-reported symptoms via 1-2 minute at-home check-ins and turns them into longitudinal, dose-aware, AI-ready datasets. It deploys as an EHR-agnostic, non-interventional observational overlay on existing oncology trials and care programs, without changing standard AE and safety workflows.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

REPROSENT offers a single unified product called the Signal Layer — a human-signal layer platform for oncology. The platform has three integrated functional components: (1) Patient-side capture — a 1–2 minute check-in where patients describe their experience in plain language mapped to structured scales; (2) Clinician context — treating teams review concise summaries in-flow, confirm grading where needed, and keep standard adverse event and safety workflows unchanged; and (3) Computable dataset — the platform turns patient data into longitudinal, dose-aware, AI-ready data for reuse across trials, programs, and models. Together, these components capture day-to-day treatment experience and make it usable for dose, safety, and development decisions.

Product and service1 record
1Signal Layer
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-powered patient engagement platform with a strong oncology community app for symptom tracking and clinician communication. Comparable as an emerging peer in oncology patient-reported symptom capture and engagement.

TypeEmerging player
Description

Decentralized clinical trial technology platform providing eCOA, ePRO, and remote data capture for biopharma. Comparable as a venture-backed peer addressing the same hybrid/overlay trial workflows as REPROSENT.

TypeDirect peer
Description

Oncology-specific patient-reported outcomes and symptom management platform used by cancer centers. Closely comparable to REPROSENT's Signal Layer for capturing tolerability data in routine oncology care and trials.

TypeDirect peer
Description

Specialist in eCOA, ePRO, and patient-centric clinical trial technology with deep oncology experience. Closely comparable to REPROSENT's Signal Layer for capturing patient-reported symptoms in oncology trials.

TypeBroad incumbent
Description

Life sciences cloud platform spanning clinical, regulatory, and commercial workflows for biopharma. Comparable as a broad incumbent whose clinical and data offerings overlap with REPROSENT's oncology trial positioning.

TypeDirect peer
Description

Industry-leading eCOA/ePRO and clinical trial technology platform serving biopharma with patient-reported outcome capture in oncology trials. Most directly comparable to REPROSENT as the dominant player in the same product category.

TypeDirect peer
Description

Clinical trial technology vendor offering eCOA, ePRO, and decentralized trial solutions to biopharma. Directly comparable in product category and target customer to REPROSENT's oncology-focused PRO overlay.

TypeBroad incumbent
Description

Global CRO and life sciences technology provider with broad RWE, eCOA, and oncology evidence offerings. Comparable as a much larger incumbent serving the same biopharma buyers with overlapping patient experience data capabilities.

TypeDirect peer
Description

Cloud-based clinical data capture platform used by sponsors and academic centers for decentralized and hybrid trials. Comparable to REPROSENT for capturing structured patient and clinician data in oncology and other therapeutic areas.

TypeEmerging player
Description

ePRO and patient-reported outcomes platform purpose-built for clinical trials with remote data capture. Comparable as a younger, eCOA-focused competitor tackling the same sponsor pain point REPROSENT addresses.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

REPROSENT

Oncology Patient-Reported Outcomes Softwarereprosent.com

REPROSENT operates the Signal Layer, an EHR-agnostic patient-reported outcomes platform for oncology clinical trials. It sells subscription licensing to biopharma development teams and cancer centers, capturing longitudinal, AI-ready symptom data outside clinic visits for reuse in HEOR, biomarkers, and AI training.

What REPROSENT does

REPROSENT is a healthcare technology company founded in 2020 and headquartered in San Francisco that operates a platform branded as the "Signal Layer," a human-signal layer for oncology clinical trials. The platform captures patient-reported symptoms and outcomes in oncology studies through an EHR-agnostic, non-interventional observational overlay, positioning REPROSENT as a data-infrastructure layer that sits between protocol-driven electronic data capture and the real-world symptom experience of cancer patients on therapy. Its core technical claim is the production of structured, AI-ready longitudinal datasets from patient-reported inputs collected outside clinic visits, including dose-aware signals that can be reused across trial programs.

The company's commercial model is subscription or recurring platform licensing, sold into biopharmaceutical development and medical teams as the primary customer segment, with a secondary segment of cooperative groups and cancer centers. Beyond core trial data capture, REPROSENT positions the platform for reuse in health economics and outcomes research (HEOR), digital biomarker development, and AI model training, implying a land-and-expand strategy where a single trial deployment seeds downstream analytic and licensing revenue. No public pricing, contract terms, customer count, or ARR figures are disclosed.

REPROSENT is a small, leanly capitalized company operating with 1-10 employees. Cumulative outside capital disclosed to date is approximately $225,000, consisting of a $125,000 investment from Y Combinator in August 2021 and a $100,000 grant from the Astellas C3 Prize in August 2022. The Astellas award is also the source of the company's only publicly named industry relationship to date. Operations are described as global despite a US-only headquarters footprint, though international commercial activity is not separately verified in the available material.

REPROSENT firmographics

Firmographics
Name
REPROSENT
Legal name
REPROSENT
Website
https://reprosent.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
REPROSENT operates the Signal Layer, an EHR-agnostic patient-reported outcomes platform for oncology clinical trials. It sells subscription licensing to biopharma development teams and cancer centers, capturing longitudinal, AI-ready symptom data outside clinic visits for reuse in HEOR, biomarkers, and AI training.
Ownership category
akta.pro rank

REPROSENT industry classification

Industry
Product category
Oncology Patient-Reported Outcomes Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
SECONDARYHLACAEAO
Patient Relationship Management (PRM) & CRM for Provider Growth (Marketing/Outreach)
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms

Keywords

  • Patient-reported outcomes
  • Oncology clinical trials
  • Tolerability data capture
  • EHR-integrated platform
  • Digital health SaaS

Where REPROSENT is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

REPROSENT business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Platform/SaaS Licensing: REPROSENT provides its human-signal layer as an observational overlay to biopharma companies, cooperative groups, and cancer centers. The platform is deployed alongside existing trials and care programs, suggesting a subscription or licensing model for enterprise clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

REPROSENT product offering

Product offering

Core offering

REPROSENT sells a "Human-Signal Layer for Oncology" called Signal Layer, a SaaS platform that captures patient-reported symptoms via 1-2 minute at-home check-ins and turns them into longitudinal, dose-aware, AI-ready datasets. It deploys as an EHR-agnostic, non-interventional observational overlay on existing oncology trials and care programs, without changing standard AE and safety workflows.

Product overview

REPROSENT offers a single unified product called the Signal Layer — a human-signal layer platform for oncology. The platform has three integrated functional components: (1) Patient-side capture — a 1–2 minute check-in where patients describe their experience in plain language mapped to structured scales; (2) Clinician context — treating teams review concise summaries in-flow, confirm grading where needed, and keep standard adverse event and safety workflows unchanged; and (3) Computable dataset — the platform turns patient data into longitudinal, dose-aware, AI-ready data for reuse across trials, programs, and models. Together, these components capture day-to-day treatment experience and make it usable for dose, safety, and development decisions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Signal Layer

Companies that use REPROSENT

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

REPROSENT technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

REPROSENT partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

REPROSENT competitors and assessment

Company assessment

Emerging players

  • Belong.Life: AI-powered patient engagement platform with a strong oncology community app for symptom tracking and clinician communication. Comparable as an emerging peer in oncology patient-reported symptom capture and engagement.
  • Medable: Decentralized clinical trial technology platform providing eCOA, ePRO, and remote data capture for biopharma. Comparable as a venture-backed peer addressing the same hybrid/overlay trial workflows as REPROSENT.
  • Yonalink: ePRO and patient-reported outcomes platform purpose-built for clinical trials with remote data capture. Comparable as a younger, eCOA-focused competitor tackling the same sponsor pain point REPROSENT addresses.

Direct peers

  • Noona (Varian/Siemens Healthineers): Oncology-specific patient-reported outcomes and symptom management platform used by cancer centers. Closely comparable to REPROSENT's Signal Layer for capturing tolerability data in routine oncology care and trials.
  • Signant Health: Specialist in eCOA, ePRO, and patient-centric clinical trial technology with deep oncology experience. Closely comparable to REPROSENT's Signal Layer for capturing patient-reported symptoms in oncology trials.
  • Medidata (Dassault Systèmes): Industry-leading eCOA/ePRO and clinical trial technology platform serving biopharma with patient-reported outcome capture in oncology trials. Most directly comparable to REPROSENT as the dominant player in the same product category.
  • Clario: Clinical trial technology vendor offering eCOA, ePRO, and decentralized trial solutions to biopharma. Directly comparable in product category and target customer to REPROSENT's oncology-focused PRO overlay.
  • Castor: Cloud-based clinical data capture platform used by sponsors and academic centers for decentralized and hybrid trials. Comparable to REPROSENT for capturing structured patient and clinician data in oncology and other therapeutic areas.

Broad incumbents

  • Veeva Systems: Life sciences cloud platform spanning clinical, regulatory, and commercial workflows for biopharma. Comparable as a broad incumbent whose clinical and data offerings overlap with REPROSENT's oncology trial positioning.
  • IQVIA: Global CRO and life sciences technology provider with broad RWE, eCOA, and oncology evidence offerings. Comparable as a much larger incumbent serving the same biopharma buyers with overlapping patient experience data capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

REPROSENT social profiles

Digital presence

REPROSENT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

REPROSENT leadership team

Management profile

Number of profiles

Profiles2 records

REPROSENT funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

REPROSENT M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REPROSENT

What does REPROSENT do?

REPROSENT sells a "Human-Signal Layer for Oncology" called Signal Layer, a SaaS platform that captures patient-reported symptoms via 1-2 minute at-home check-ins and turns them into longitudinal, dose-aware, AI-ready datasets. It deploys as an EHR-agnostic, non-interventional observational overlay on existing oncology trials and care programs, without changing standard AE and safety workflows.

Is REPROSENT a public or private company?

REPROSENT is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was REPROSENT founded?

REPROSENT was founded in 2020. It employs 1 to 10 people.

Where is REPROSENT based?

REPROSENT is headquartered in San Francisco, United States, in the North America region.

How does REPROSENT make money?

One revenue line is on record: platform/SaaS Licensing.

Who are REPROSENT's main competitors?

Emerging players on record are Belong.Life, Medable and Yonalink. Direct peers are Noona (Varian/Siemens Healthineers), Signant Health, Medidata (Dassault Systèmes), Clario and Castor. Broad incumbents are Veeva Systems and IQVIA.

Does REPROSENT have an API?

No public API is recorded for REPROSENT.

What industry is REPROSENT in?

REPROSENT's product category is Oncology Patient-Reported Outcomes Software. Its primary akta.pro industry code is HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms, with a secondary code of HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation. Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AstellasAstellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovation in Cancer Care Beyond MedicineAstellas Pharma US, Inc. announced REPROSENT as the grand prize winner of its sixth annual C3 Prize, awarding a $100,000 grant to support the company's digital app for cancer patient symptom tracking. The initiative aims to improve cancer care by empowering patients and caregivers with data-driven tools to enhance communication with healthcare providers. Astellas will also provide hands-on support through partners Slalom and MATTER to help scale the solution.PR NewswireAstellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovation in Cancer Care Beyond MedicineAstellas Pharma US, Inc. announced Aimee DeGolyer as the grand prize winner of the sixth annual C3 Prize for her development of an app designed to empower cancer patients. DeGolyer, who is the Founder & CEO of REPROSENT, will receive a $100,000 grant and support to help scale access to more patients in the cancer community. The C3 Prize aims to foster innovation in cancer care that goes beyond traditional medicine.BioSpaceAstellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovation in Cancer Care Beyond MedicineAstellas Pharma US, Inc. announced REPROSENT as the 2022 Grand Prize winner of its sixth annual C3 Prize for innovation in cancer care. Founder Aimee DeGolyer will receive a $100,000 grant along with support from Slalom and MATTER to scale her digital app designed to help cancer patients track symptoms and improve communication with healthcare providers.